Abstract
Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Protein & Peptide Letters
Title:Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Volume: 20 Issue: 4
Author(s): Michele Caraglia, Alessandra Dicitore, Monica Marra, Sara Castiglioni, Luca Persani, Pasquale Sperlongano, Pierosandro Tagliaferri, Alberto Abbruzzese and Giovanni Vitale
Affiliation:
Keywords: Type I interferons, interferon-alpha, interferon-beta, STATs, mTOR, pegylated interferons, farnesyltransferase inhibitors, EGF-R, cytokine, antitumor activity
Abstract: Type I interferons (IFNs) represent a group of cytokines that act through a common receptor composed by two chains (IFNAR-1 and IFNAR-2). Several in vitro and in vivo studies showed a potent antitumor activity induced by these cytokines. IFN-, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of cancer cell growth and differentiation, affecting cellular communication and signal transduction pathways. IFN-, is currently the most used cytokine in the treatment of cancer. However, the potential anti-tumour activity of IFN- is limited by the activation of tumour resistance mechanisms. This article reviews the current knowledge about the antitumor activity of type I IFNs, focusing on new potential strategies able to strengthen the antitumor activity of these cytokines.
Export Options
About this article
Cite this article as:
Caraglia Michele, Dicitore Alessandra, Marra Monica, Castiglioni Sara, Persani Luca, Sperlongano Pasquale, Tagliaferri Pierosandro, Abbruzzese Alberto and Vitale Giovanni, Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040005
DOI https://dx.doi.org/10.2174/0929866511320040005 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Characteristics of Brain Tumor Stem Cells and the Rationale for Applying Tyrosine Kinase Inhibitors as Potential Targeting Agents
Recent Patents on Regenerative Medicine Integrase Interactor 1 in Health and Disease
Current Protein & Peptide Science Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry Synthesis of First Generation Dendron, GABA Caged Bis-1,2 -(4- acetylphenylethynyl)-4,5-dimethoxybenzene for Photorelease Study
Letters in Organic Chemistry Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design IL-24: Physiological and Supraphysiological Effects on Normal and Malignant Cells
Current Medicinal Chemistry Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry Prevention of Intracerebral Haemorrhage
Current Drug Targets Anti-Infective Protective Properties of S100 Calgranulins
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Current Issues in the Utility of Blood Oxygen Level Dependent MRI for the Assessment of Modulations in Tumor Oxygenation
Current Medical Imaging Cytotoxicity of a Vanadyl(IV) Complex with a Multidentate Oxygen Donor in Osteoblast Cell Lines in Culture
Medicinal Chemistry